Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Ventyx Doses First Subject in VTX-958 Trial for Selective Allosteric TYK2 Inhibitor

americanpharmaceuticalreviewMarch 23, 2021

Tag: Ventyx , VTX-958 , TYK2 Inhibitor

PharmaSources Customer Service